PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and Use in Patients

Advances in Experimental Medicine and Biology
Abraham Abuchowski

Abstract

Oxygen transfer agents have long been sought as a means to treat hypoxia caused by congenital or acquired conditions. Hemoglobin-based oxygen carriers were in clinical development as blood substitutes, but development was halted due to the finding of significant vasoactivity. Rather than develop a blood substitute, a product for indications characterized by hypoxia is in development. PEGylated bovine carboxyhemoglobin (SANGUINATE™) is both a carbon monoxide releasing molecule and an oxygen transfer agent. It is comprised of three functional components that act to inhibit vasoconstriction, reduce inflammation and optimize the delivery of oxygen. SANGUINATE has the potential to reduce or prevent the effects of ischemia by inhibiting vasoconstriction and re-oxygenating tissue. Phase 1 safety trials in healthy volunteers were completed in 2013. SANGUINATE was shown to be safe and well tolerated with no serious adverse effects. Phase Ib studies have been completed in stable patients with Sickle Cell Disease. SANGUINATE has also been administered to two patients under emergency use protocols. Both patients exhibited improved status following treatment with SANGUINATE.

Citations

Apr 20, 2017·The New England Journal of Medicine·Frédéric B PielDavid C Rees
Apr 18, 2017·Journal of Pharmaceutical Sciences·Kazuaki TaguchiMasaki Otagiri
Mar 25, 2017·Journal of Functional Biomaterials·Kazuaki TaguchiMasaki Otagiri
Mar 30, 2018·The Annals of Pharmacotherapy·Sean M McConachieSheila M Wilhelm
Mar 7, 2019·The Journal of Pharmacology and Experimental Therapeutics·Katja B Ferenz, Andrea U Steinbicker
Oct 23, 2019·The Journal of Applied Laboratory Medicine·Merih T TesfazghiMelanie L Yarbrough
Nov 14, 2018·Current Medicinal Chemistry·Kazuaki TaguchiMasaki Otagiri
Sep 28, 2017·The New England Journal of Medicine·Jeffrey L CarsonPaul M Ness
Dec 6, 2018·Nature Reviews. Drug Discovery·Marilyn J TelenGregory M Vercellotti
Feb 12, 2019·Artificial Cells, Nanomedicine, and Biotechnology·William H NugentBjorn K Song
Nov 5, 2019·American Journal of Clinical Pathology·Sara Emily BachertLeonard I Boral
Jul 31, 2016·Transfusion·Linda M S ResarSteven M Frank
Mar 30, 2019·Anesthesia and Analgesia·Jonathan S JahrAryeh Shander

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Transfusion clinique et biologique : journal de la Société française de transfusion sanguine
R M Winslow
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
P GonzalezE P Orringer
© 2022 Meta ULC. All rights reserved